Fri, Oct 31, 2014, 7:50 PM EDT - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Ocean Power Technologies, Inc. Message Board

fearingsf 18 posts  |  Last Activity: Oct 22, 2014 12:52 AM Member since: Jan 11, 2008
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • A paralysed man has been able to walk again after a pioneering therapy that involved transplanting cells from his nasal cavity into his spinal cord.

    The complex neural circuitry responsible for our sense of smell is the only part of the nervous system that regenerates throughout adult life.

    It is this ability that scientists have tried to exploit in stimulating repair in the spinal cord.

    Every time we breathe, molecules carrying different odours in the air come into contact with nerve cells in the nose.

    These transmit messages to our olfactory bulbs - at the very top of the nasal cavity, sitting at the base of the brain.

    The nerve cells are being continually damaged and must be replaced.

    This process of regeneration is made possible by olfactory ensheathing cells (OECs), which provide a pathway for the fibres to grow back.

  • fearingsf fearingsf Oct 22, 2014 12:45 AM Flag

    The complex neural circuitry responsible for our sense of smell is the only part of the nervous system that regenerates throughout adult life.

    It is this ability that scientists have tried to exploit in stimulating repair in the spinal cord.

    Every time we breathe, molecules carrying different odours in the air come into contact with nerve cells in the nose.

    These transmit messages to our olfactory bulbs - at the very top of the nasal cavity, sitting at the base of the brain.

    The nerve cells are being continually damaged and must be replaced.

    This process of regeneration is made possible by olfactory ensheathing cells (OECs), which provide a pathway for the fibres to grow back.

  • A Bulgarian man who was paralyzed from the chest down in a knife attack can now walk with the aid of a frame after receiving pioneering transplant treatment using cells from his nose.

    The technique, described as a breakthrough by a study in the journal Cell Transplantation, involved transplanting what are known as olfactory ensheathing cells into the patient’s spinal cord and constructing a “nerve bridge” between two stumps of the damaged spinal column.
    “We believe... this procedure is the breakthrough which, as it is further developed, will result in a historic change in the currently hopeless outlook for people disabled by spinal cord injury,” said Geoffrey Raisman, a professor at University College London’s (UCL) institute of neurology, who led the research.

  • Another method of operation. CYTR

    About Aldoxorubicin

    The widely used chemotherapeutic agent doxorubicin is delivered systemically and is highly toxic, which limits its dose to a level below its maximum therapeutic benefit. Doxorubicin also is associated with many side effects, especially the potential for damage to heart muscle at cumulative doses greater than 450 mg/m2. Aldoxorubicin combines doxorubicin with a novel single-molecule linker that binds directly and specifically to circulating albumin, the most plentiful protein in the bloodstream. Protein-hungry tumors concentrate albumin, thus increasing the delivery of the linker molecule with the attached doxorubicin to tumor sites. In the acidic environment of the tumor, but not the neutral environment of healthy tissues, doxorubicin is released. This allows for greater doses (3 ½ to 4 times) of doxorubicin to be administered while reducing its toxic side effects. In studies thus far there has been no evidence of clinically significant effects of aldoxorubicin on heart muscle, even at cumulative doses of drug well in excess of 2,000 mg/m2.

  • Two promising candidate vaccines

    Given the public health need for safe and effective Ebola interventions, WHO regards the expedited evaluation of all Ebola vaccines with clinical grade material as a high priority.

    Two candidate vaccines have clinical-grade vials available for phase 1 pre-licensure clinical trials.

    One (cAd3-ZEBOV) has been developed by GlaxoSmithKline in collaboration with the US National Institute of Allergy and Infectious Diseases. It uses a chimpanzee-derived adenovirus vector with an Ebola virus gene inserted.

    The second (rVSV-ZEBOV) was developed by the Public Health Agency of Canada in Winnipeg. The license for commercialization of the Canadian vaccine is held by an American company, the NewLink Genetics company, located in Ames, Iowa. The vaccine uses an attenuated or weakened vesicular stomatitis virus, a pathogen found in livestock; one of its genes has been replaced by an Ebola virus gene.

  • Harvard Stem Cell Institute has shown that a protein called GDF11 may be closely related to this decline in functionality. GDF11 circulates in much higher concentrations in the bodies of young mice as well as humans, and decreases as we age. There obviously existed a correlation, though causation was not clear.

    That changed with this study, titled Restoring Systemic GDF11 Levels Reverses Age-Related Dysfunction in Mouse Skeletal Muscle, led by Doctors Richard Lee and Amy Wagers. I’ve written about this study before, but it deserves a lot more attention, as its consequences are so important.

    It demonstrated that the decrease in GDF11 is directly linked to hypertrophy. The flip side of this discovery is the real news here. The study showed that increasing levels GDF11 in the bloodstream causes shrinking of the heart back to healthy size. GDF11, which stands for growth differentiation factor 11, or bone morphogenic protein 11, is the name of a protein in the very important transforming growth factor (TGF-β) family.

    Researchers observed and measured the heart size of old mice versus old mice that had had blood from younger mice introduced into their circulatory systems. Before the treatment, the old mice had larger hearts due to the inflammatory action I mentioned above. After the treatment of young blood, however, the hearts of the old mice began to resemble young, healthy hearts.

  • fearingsf by fearingsf Sep 13, 2014 12:28 AM Flag

    Under its Biorefinery Assistance Program, the U.S. Department of Agriculture (USDA) is providing a $105 million loan guarantee to Fulcrum Sierra Biofuels, LLC, a unit of Fulcrum BioEnergy, Inc. (Pleasanton, CA), to support the development of a biorefinery that will produce jet fuel from municipal solid waste (MSW).

    Fulcrum was founded in 2007 by James A.C. McDermott, the Managing Partner of US Renewables Group, to pioneer the development of a reliable and efficient process for converting garbage into renewable transportation fuels.

    Since 2007, Fulcrum has entered into strong strategic relationships with its feedstock, technology and fuel off-take partners. These partnerships have set the table for explosive growth for Fulcrum. We have demonstrated our technology and our long-term, zero-cost feedstock agreements give us the raw materials to produce hundreds of millions of gallons of low-carbon fuel annually.

    Since its founding in 2007, Fulcrum BioEnergy has been backed by US Renewables Group and Rustic Canyon Partners, two leading venture capital firms in the clean energy space. In addition, Waste Management and Cathay Pacific Airways have become valued equity partners in the Company. Fulcrum is well-positioned to execute on its aggressive plan to build garbage-to-fuels plants across North America and around the world.

    From China, we hear that Cathay Pacific Airways has announced a strategic investment in Fulcrum BioEnergy, and negotiated a long-term supply agreement with Fulcrum for an initial 375 million US gallons of sustainable aviation fuel over 10 years (representing on an annual basis approximately 2% of the airline’s current fuel consumption) that meets all the airline’s technical requirements and specifications.

    Fulcrum’s process utilizes a steam-reforming gasification system manufactured and licensed by ThermoChem Recovery International, Inc. (TRI) and a Fischer-Tropsch gas-to-liquids technology licensed from Emerging Fuels Technology to convert MSW into synthetic paraffinic kerosene (SPK) jet fuel and diesel.

    Fulcrum has incorporated these technologies in a fully integrated process demonstration plant and has proven and demonstrated that this process will efficiently and economically convert MSW to low-carbon fuels.

    Fulcrum uses the heat created by the process to generate electricity for the plant, not only lowering the cost of production, but also shrinking the carbon footprint. The technology is engineered to be modular and scalable to meet the needs of our markets, from a 10 million gallon per year plant to a 60 million gallon per year plant.

  • Reply to

    52 week low was $1.19... now it goes to $0.50

    by apfappa Sep 11, 2014 5:55 PM
    fearingsf fearingsf Sep 11, 2014 11:11 PM Flag

    Enterprise valued at cash ? Nice discount? Get better?

  • fearingsf by fearingsf Sep 10, 2014 4:59 PM Flag

    After Hours Volume: After Hours High: After Hours Low:
    200 $ 2.43 $ 2.43
    (16:01:14 PM)

    Yeah, right ! Move along.

  • fearingsf by fearingsf Sep 5, 2014 5:49 PM Flag

    Rare mutations

    One gene – apolipoprotein B – had rare mutations in all three long-lived families that were less common in the 800 controls. The protein made by this gene helps carry "bad cholesterol" in the blood, high levels of which lead to heart attacks. It is possible that the mutations reduce levels of this bad cholesterol.

    The team is now investigating whether the centenarians' cholesterol levels bear out this theory. If they do, "this would definitely reinforce the idea that cardiovascular health is an important factor in overall ageing", says Cash.

    Intriguingly, previous work has shown that another gene for which there is strong evidence for a role in human lifespan is apolipoprotein E, which also helps transport cholesterol. However, the beneficial variants of this gene also reduce the risk of Alzheimer's disease, which is usually thought to be the main reason behind their effects on longevity.

    Another gene that has recently been implicated in longevity is FOXO3A, which may affect people's sensitivity to insulin.

  • fearingsf fearingsf Sep 5, 2014 1:37 PM Flag

    Perhaps a rush to sell as margin calls and institutional exits due to too low share price come in. They nmust sell for now.

  • fearingsf by fearingsf Sep 3, 2014 11:25 PM Flag

    Shaugn Stanley – MBII Board Member

    Shaugn Stanley is currently Senior Managing Director at Stifel Financial and joined the MBI board of directors in 2012. One of the seven founding members of Thomas Weisel Partners, which was sold to Stifel Financial in July 2010, Stanley held a number of senior positions including CFO and Director of Private Client Services during his 12-year tenure at Thomas Weisel Partners. Prior to that, Stanley was CFO at Montgomery Securities, and SVP, CFO and Group Risk Manager for Fidelity Investments Brokerage Group in Boston. Stanley began his career as an accountant at Deloitte.
    Shaugn received a BBA in Accounting from Stephen F. Austin State University, and is a licensed (inactive) Certified Public Accountant.

  • fearingsf fearingsf Sep 3, 2014 2:37 PM Flag

    Searching, searching...

    Hector Absi, Chief Operating Officer, has notified the Company of his resignation for personal reasons, effective as of August 22, 2014.

    Mr. Absi has agreed to remain with the Company as a consultant to ensure a smooth transition. Efforts to initiate a search for a successor are underway.

  • Typically any cannot hold shares below a set share price, say $5, or market cap, say $100 - $300 mil, so selling could increase till maybe 3-4 mil shares are given up. Yikes !

  • After Hours Volume: After Hours High: After Hours Low:
    124,548 $ 8.40
    (17:42:45 PM) $ 7.6102
    (16:02:16 PM)

  • On that I’m on the record arguing that the Chinese property market may trigger the event some time after 2015. But another scenario that is a persuasive alternative is the Jeremy Grantham theory of a 2016 bubble bust for US markets following its Presidential election. On that Goldman today provides a nice trigger:

    The S&P 500 will generate an annualised total return of 6 per cent between now and 2018 when Fed funds reach a “neutral” level of 4 per cent…We assume a neutral Fed funds rate will be reached in 2018, and 10-year Treasuries will yield 4.5 per cent. Our baseline scenario implies an annualised total return of 1 per cent on a constant maturity 10-year Treasury note through year-end 2018…Buying a 10-year Treasury note and holding it through 2018 would also generate a nominal annualised return of 1 per cent.

    If we ever reach 4% I will very happily eat my hat.

    Reserve Bank of India Governor Raghuram Rajan warned Wednesday that the global economy bears an increasing resemblance to its condition in the 1930s, with advanced economies trying to pull out of the Great Recession at each other’s expense.

    The difference: competitive monetary policy easing has now taken the place of competitive currency devaluations as the favored tool for playing a zero-sum game that is bound to end in disaster. Now, as then, “demand shifting” has taken the place of “demand creation,” the Indian policymaker said.

    As was the case in the 1930s, the lack of coordination between policymakers is producing spillovers that may be difficult to control, and the world’s financial system may soon face fresh turbulence at a time when central banks have yet to repair the damage that the 2008 financial crisis caused to developed economies.

    “We are taking a greater chance of having another crash at a time when the world is less capable of bearing the cost,” said Mr. Rajan in an interview with the Central Banking Journal.

    Before you write this off as the ramblings of a subaltern crackpot, recall that it was Raghuram Rajan that warned in August 2005 that:

    Developments in the financial sector have led to an expansion in its ability to spread risks. The increase in the risk bearing capacity of economies, as well as in actual risk taking, has led to a range of financial transactions that hitherto were not possible, and has created much greater access to finance for firms and households. On net, this has made the world much better off. Concurrently, however, we have also seen the emergence of a whole range of intermediaries, whose size and appetite for risk may expand over the cycle. Not only can these intermediaries accentuate real fluctuations, they can also leave themselves exposed to certain small probability risks that their own collective behavior makes more likely. As a result, under some conditions, economies may be more exposed to financial-sector-induced turmoil than in the past. The paper discusses the implications for monetary policy and prudential supervision. In particular, it suggests market-friendly policies that would reduce the incentive of intermediary managers to take excessive risk.

    He issued this warning at the FOMC’s Jackson Hole gathering where he was greeted with genteel jeering and was publicly dressed down by Larry Summers.

    Rajan was proven very precisely to be right. Unfortunately he is almost certainly right again this time. The only question is when.

  • ORBACTIV™ (Oritavancin) for injection is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms:

    Staphylococcus aureus (including methicillin-susceptible and methicillin–resistant isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only).

  • some workout job here !

    Washington, D.C.- Over 100 economists, including Nobel laureate Robert Solow, Branko Milanovic and Dani Rodrik called on Congress today to take action to mitigate the harmful fallout from the recent ruling by Judge Griesa of the U.S. District Court for the Southern District of New York that requires Argentina to pay holdout creditors at the same time as the majority of creditors. The letter warns that “The District Court’s decision – and especially its injunction that is currently blocking Argentina from making payments to 93 percent of its foreign bondholders -- could cause unnecessary economic damage to the international financial system, as well as to U.S. economic interests, Argentina, and fifteen years of U.S. bi-partisan debt relief policy.”

    “It’s a widely shared opinion among economists that the court’s attempt to force Argentina into a default that nobody – not the debtor nor more than 90 percent of creditors – wants, is wrong and damaging,”

0.9932-0.0368(-3.57%)Oct 31 3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.